Search

Search results

65 results found

mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide.

Publication: Journal Article

Matsumoto, Akinobu, Alessandra Pasut, Masaki Matsumoto, Riu Yamashita, Jacqueline Fung, Emanuele Monteleone, Alan Saghatelian, Keiichi I Nakayama, John G Clohessy, and Pier Paolo Pandolfi. 2017. “MTORC1 and Muscle Regeneration Are Regulated by the LINC00961-Encoded SPAR Polypeptide.”. Nature 541 (7636): 228-32.

Of model pets and cancer models: an introduction to mouse models of cancer.

Publication: Journal Article

Lunardi, Andrea, Caterina Nardella, John G Clohessy, and Pier Paolo Pandolfi. 2014. “Of Model Pets and Cancer Models: An Introduction to Mouse Models of Cancer.”. Cold Spring Harbor Protocols 2014 (1): 17-31.

Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.

Publication: Journal Article

Nardella, Caterina, Andrea Lunardi, Giuseppe Fedele, John G Clohessy, Andrea Alimonti, Sara C Kozma, George Thomas, Massimo Loda, and Pier Paolo Pandolfi. 2011. “Differential Expression of S6K2 Dictates Tissue-Specific Requirement for S6K1 in Mediating Aberrant MTORC1 Signaling and Tumorigenesis.”. Cancer Research 71 (10): 3669-75.

beta-tting on p63 as a metastatic suppressor.

Publication: Journal Article

Clohessy, John G, and Pier Paolo Pandolfi. 2009. “Beta-Tting on P63 As a Metastatic Suppressor.”. Cell 137 (1): 28-30.

Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Publication: Journal Article

Nardella, Caterina, Arkaitz Carracedo, Andrea Alimonti, Robin M Hobbs, John G Clohessy, Zhenbang Chen, Ainara Egia, et al. 2009. “Differential Requirement of MTOR in Postmitotic Tissues and Tumorigenesis.”. Science Signaling 2 (55): ra2.

In Vivo Protocol Design and Implementation

Page

Agents alone or in combination will be evaluated in vivo in human tumor xenografts in mice, as well as in GEMs obtained by outsourcing or in-house acquisition when requested. We will evaluate each drug or combination of drugs by different routes or different schedules of administration following...

Procedures and Policies

Page

Proper Citation Beth Israel Deaconess Medical Center - Preclinical Murine Pharmacogenetics Facility, RRID: SCR_026599 From an Idea to Its Realization An investigator has an idea for a new preclinical trial and takes it to Core Director for consultation. The Core Director provides advise in the study...

About Us

Page

Improving Human Health Through Preclinical Trials in Mouse Models of Human Disease The goal of our facility, which is partially funded by Dana Farber/Harvard Cancer Center, is to provide expertise in the design and implementation of preclinical trials to test new drugs, drug combinations and novel...

PI3K drives the de novo synthesis of coenzyme A from vitamin B5.

Publication: Journal Article

Dibble, Christian C, Samuel A Barritt, Grace E Perry, Evan C Lien, Renee C Geck, Sarah E DuBois-Coyne, David Bartee, et al. 2022. “PI3K Drives the de Novo Synthesis of Coenzyme A from Vitamin B5.”. Nature 608 (7921): 192-98.

WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.

Publication: Journal Article

Kishikawa, Takahiro, Hiroshi Higuchi, Limei Wang, Nivedita Panch, Valerie Maymi, Sachem Best, Samuel Lee, et al. 2021. “WWP1 Inactivation Enhances Efficacy of PI3K Inhibitors While Suppressing Their Toxicities in Breast Cancer Models.”. The Journal of Clinical Investigation 131 (24).